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Abstract
Background: Data regarding long-term follow-up of radiofrequency catheter ablation (RFCA) of ac-
cessory pathways (APs) in patients with Ebstein’s anomaly (EA) are limited. The procedures are chal-
lenging due to multiple or wide APs.
Methods: Analysis was performed on clinical and periprocedural data of patients with EA referred to 
the centre in order to perform catheter ablation of AP. The group consisted of 22 patients (female 40.9%, 
mean age 33.6 ± 19.1 years). The follow-up utilized electrocardiogram and Holter monitoring.
Results: Twenty-two patients had 33 accessory pathways (8 patients had multiple APs, 11 patients 
broad AP). Twenty-nine different arrhythmias were ablated: 20 orthodromic atrioventricular reciprocat-
ing tachycardia (O-AVRT), 5 antidromic atrioventricular reciprocating tachycardia (A-AVRT), 3 slow/
fast atrioventricular nodal reentry tachycardia (s/f AVNRT) and 1 cavotricuspid-isthmus-dependent 
atrial flutter (CTI-AFL). In 3 (13.6%) patients multiple ablation targets for RFCA ablation were ob-
served. The acute procedural success rate after the first RFCA performed was: 100% for AVNRT, 77.3% 
for APs and 50.0% for CTI-AFL ablation. Follow-up (mean 95.7 ± 49.8 months) was completed in 
86.4% of patients. One patient had paroxysmal atrial fibrillation not targeted during ablation. One pa-
tient died due to heart failure 12 years after RFCA. Three patients who underwent RFCA of accessory 
pathways in the mid-1990s were lost in follow-up. 
Conclusions: Radiofrequency ablation in patients with EA is challenging but safe and have a high 
short-term as well as long-term success rate. (Cardiol J 2017; 24, 1: 1–8)
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Introduction
Ebstein’s anomaly (EA) is a rare congenital heart 
disorder that accounts for < 1% of all patients with 
congenital heart disease and is characterized by apical 
displacement of the posterior and septal leaflets of 
the tricuspid valve with discontinuity of the central 
fibrous body and septal atrioventricular ring [1]. 
Arrhythmias are the main symptom in adolescents 
and adults as well as a major clinical problem [2]. 
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Wolff-Parkinson-White (WPW) syndrome is more 
frequently associated with EA than with any other 
congenital heart defect [3–5]. According to the 
existing literature, up to 50% of patients with EA 
have accessory, frequently multiple pathways (AP) 
[4, 6, 7]. Abnormal anatomy can also results in ac-
tivation abnormalities including delayed intraatrial 
conduction and right bundle branch block [8, 9].
According to current guidelines, patients with 
EA and relevant arrhythmias should be referred for 
an electrophysiological study followed, if needed, 
by ablation therapy, or surgical treatment of the 
arrhythmias in the case of a planned heart surgery 
[10]. Moreover, the current guidelines concerning 
the management of patients with supraventricular 
arrhythmias suggest that EA might present a sud-
den cardiac death risk factor [11].
Abnormal, fractionated potentials, enlarged 
cavities of the heart and the presence of multiple 
APs make the ablation procedure more complicated 
and challenging.
There is a limited number of reports published 
on ablation results in patients with EA and WPW. 
The published data report small groups of patients 
and relatively short follow-up (from 12 ± 7 to 
54 ± 34 months) [12–14].
The aim of this study was to analyse the safety and 
efficacy of radiofrequency catheter ablation (RFCA) of 
accessory pathways in longer follow-ups within one of 
the largest cohorts of ablated patients with EA.
Methods
Study patients
The group consisted of 22 patients with EA 
and who had been referred to our centre as 
a tertiary, experienced centre in ablative therapy of 
congenital heart disease. The patients were rela-
tively young — mean age 33.6 ± 19.1 years and 
predominantly male (58.1%). 
Definitions
In order to diagnose EA, the apical displace-
ment of the commissure between the septal and 
posterior leaflets of the tricuspid valve in relation 
to the anterior mitral valve leaflet by > 8 mm/m2 
body surface area had to be observed [15].
Multiple APs (or an AP with multiple ventricu-
lar or atrial insertions) and broad AP were defined 
as previously described [16, 17].
The correct ablation site in patients with 
broad or multiple AP was identified on the basis 
of a change in the surface of electrocardiographic 
(ECG) morphology and/or a delay in the local 
activation time during radiofrequency (RF) ap-
plication [17].
Atrial flutter required the cavotricuspid isth-
mus (CTI-AFL) to be the part of a macroreentrant 
right atrial tachycardia [5].
The following serious adverse events attrib-
uted to catheter ablation were defined: death, atrio-
ventricular block, cardiac perforation, coronary 
artery involvement or thromboembolic events.
Procedure
An electrophysiological study was performed 
in the fasted and sedated state. All patients signed 
an informed consent form prior to the ablation 
procedure. Heparin bolus was given at a dosage of 
50–100-IU/kg, and after each consecutive hour — 
a heparin bolus of 1000 IU. Intracardiac bipolar elec-
trograms as well as 12-lead ECG were recorded digi-
tally. All measurements were performed using on-
screen electronic callipers at a sweep speed of 100– 
–200 mm/s and gain setting of 0.1–0.2 mV/cm. The 
following catheters, in accordance with the study 
protocol, were used: (i) a 7 F steerable, diagnostic 
quadripolar catheter with 2–5–2 mm inter-electrode 
spacing (Marinr MCXL, Medtronic, Inc., Minneapo-
lis, MN, USA) placed in the coronary sinus; (ii) abla-
tion catheters: an 8 F irrigated tip catheter or 8 mm 
tip DS catheter. In the mid-1990s, three diagnostic 
electrodes were used. In use for this study was the 
3-dimensional system CARTO XP, CARTO 3 system 
(Biosense Webster, Inc., Diamond Bar, CA, USA) 
or EnSite™  NavX (St. Jude Medical, St. Paul, Mn, 
USA) and long sheath routinely, since 2002.
Follow-up
The follow-up data were obtained from hospital 
and outpatient clinic records. The evaluation of the 
patients comprised: physical examination, a 12-lead 
ECG, echocardiography and Holter monitoring 
performed in all patients a minimum of 4 times.
Holter monitoring was performed at intervals 
of 6 months during the first year subsequent to the 
last successful RFCA procedure and at intervals of 
12 months thereafter.
Patients were systematically asked about symp-
toms of recurrent arrhythmias and encouraged to 
notify the clinic in the case of recurrence at any time 
during the follow-up period. Patients with recurrent 
arrhythmia were offered a repeat ablation.
Statistical analysis
Categorical variables were expressed as num-
bers and percentages, continuous variables as 
median and range or mean with 1 standard de-
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viation, respectively. Categorical variables were 
compared with the use of c2 test. A p value < 0.05 
was considered statistically significant. Analyses 
were performed using SPSS software.
Results 
Study population
Twenty-two patients with EA (female 40.9%, 
mean age 33.6 ± 19.1 years) were admitted to 
a centre experienced in ablative therapy of con-
genital heart disease in order to perform RFCA 
of accessory pathways between 1993 and 2015 
(Tables 1, 2). 
The patients’ evaluation comprised of clini-
cal history, physical examination, a 12-lead ECG, 
Table 1. Patient characteristics.
Pt. Sex Age Age of first  
arrhythmia episode
Ablation targets Total no.  
of ablations
Reason for  
multiple procedures
1 M 18 16 1 broad AP, A-AVRT 3 AP
2 F 42 7 2 APs, O-AVRT 1 –
3 M 33 1 2 APs, O-AVRT 1 –
4 F 13 3 1 broad AP, O-AVRT 1 –
5 F 13 1 1 broad AP, O-AVRT, 
s/f AVNRT
1 –
6 M 18 NA 1 broad AP, O-AVRT 1 –
7 M 68 5 1 broad AP, O-AVRT, 
s/f AVNRT
3 AP
8 M 53 NA 1 AP, O-AVRT 1 –
9 F 49 NA 2 APs, 1 broad AP,  
O-AVRT
1 –
10 M 27 6 2 APs, O-AVRT 3 AP
11 F 47 NA 1 AP, O-AVRT,  
s/f AVNRT, CTI-AFL
2 CTI-AFL
12 F 18 1 2 APs, O-AVRT 1 –
13 F 74 NA 1 broad AP, O-AVRT 3 AP
14 M 14 11 2 APs, 1 broad,  
O-AVRT, A-AVRT
1 –
15 F 53 13 1 AP, O-AVRT 1 –
16 M 25 NA 1 AP, A-AVRT 1 –
17 F 60 NA 1 broad AP, O-AVRT 1 –
18 M 34 NA 1 broad AP, O-AVRT 3 AP
19 M 29 NA 1 AP, O-AVRT 2 AP
20 M 19 NA 3 APs 1 –
21 M 17 NA 3 APs, A-AVRT,  
O-AVRT
4 AP
22 M 16 NA 1 broad AP 5 AP
A-AVRT — antidromic atrioventricular reentrant tachycardia; AP — accessory pathway; AV — atrioventricular node; s/f AVNRT — slow/fast 
atrioventricular nodal reentrant tachycardia; CTI-AFL — cavotricuspid isthmus-dependent atrial flutter; F — female; M — male; NA — not 
available; O-AVRT — orthodromic atrioventricular reentrant tachycardia
Table 2. Procedural data.
Parameters AP (n = 22)
Previous cardiac surgery 4 (18.2%)
Age at first ablation [years] 33.6 ± 19.1
One ablation, in our lab 14 (63.6%)
Two ablations in our lab 5 (22.8%)
Three ablations in our lab 3 (13.6%)
Number of ablationsoutside our centre 10 (45.5%)
Two ablations outside our centre 5 (22.8%)
Total number of interventions 40
3D system in our lab 18 (81.8%)
Long sheath in our lab 15 (62.5%)
Long-term success 95.5%
AP — accessory pathway; 3D — three-dimensional
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24-h Holter-ECG monitoring, echocardiography, 
electrophysiological study parameters and coro-
nary angiography in patients with the risk factors 
for ischemic heart disease. Mean left ventricular 
ejection fraction was 62.2%. 
Sixteen patients underwent ablation with the 
use of CARTO XP or CARTO 3 system (Biosense 
Webster) and 2 patients using EnSite™ NavX (St. Jude 
Medical). Four patients treated in the 1990s underwent 
ablation without a 3-dimensional navigation system.
The mean procedure time was 155.0 ± 74.0 
(range 60–240) min, the mean fluoroscopy time 
was 10.1 ± 3.6 min and mean fluoroscopy exposure 
90.5 ± 82.2 mGym2.
Twenty-two patients with AP had 40 RFCA 
(mean 1.8; range 1–4), 33 of them at the centre 
(mean 1.5; range 1–3). Eighteen (81.8%) patients 
had overt pre-excitation, 1 (4.6%) intermittent 
and 3 (13.6%) had concealed AP. Thirty-two APs 
(3 left-sided) were targeted with ablation. 
Figure 1. Baseline 12 lead electrocardiogram (A) and electrocardiogram after the radiofrequency ablation of 3 accessory 
pathways (B).
Figure 2. 12 lead electrocardiogram (A) and intracardiac recording (B) of cavotricuspid isthmus-dependent atrial flutter 
conducted through 2 accessory pathways, left posterosuperior (1) and broad right inferior/paraseptal (2). 
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Figure 3. 12 lead electrocardiogram (A) and intracardiac recordings (B) of antidromic atrioventricular reentrant tachy-
cardia conducted through left posteroinferior accessory pathway.
Eight (36.4%) patients had multiple APs, 
11 (50.0%) patients had broad AP. Three (13.6%) 
patients had 3 APs (Figs. 1–4).
All patients with APs had palpitations or 
documented arrhythmias (mean age at the time of 
first episode 6.9 ± 5.6; range 1–16 years). Twenty 
patients had documented orthodromic atrioven-
tricular reciprocating tachycardia (O-AVRT), 5 an-
tidromic atrioventricular reciprocating tachycardia 
(A-AVRT), 3 patients had slow/fast atrioventricular 
nodal reciprocating tachycardia (s/f AVNRT), 
1 atrial flutter (CTI-AFL).
In 1 patient with AP and CTI-AFL, there was 
a failure to block the CTI during first procedure, 
(Table 1, Patient no. 11) during the second proce-
dure the CTI was successfully blocked.
Three patients had O-AVRT and A-AVRT 
episodes, 2 patients only A-AVRT. 
One patient with 3 APs had ventricular fibrilla-
tion (VF) episode and was considered as an end point 
of the first arrhythmic event. Eight (36.4%) patients 
with APs had more than one type of arrhythmia, 
1 patient had 3 types (4.5%). Four patients had 
a history of cardiac surgery (Fig. 5; Table 3).
Figure 4. 12 lead electrocardiogram (A) and intracardiac recordings (B) of orthodromic atrioventricular reentrant 
tachycardia conducted through left posteroinferior accessory pathway. 
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Table 3. Patients with a history of cardiac surgery.
Pt. Number  
of surgical  
procedures 
prior to RF
Surgical  
procedures
Arrhythmias Ablation Number  
of RF  
ablations
Time from 
surgery 
to first RF 
[years]
Arrhythmia 
during  
follow-up
1 1 ASD closure, 
VSD closure, 
PDA closure
O-AVRT MAP,  
inferoparaseptal  
and right inferior
1 17 No
2 1 TVR A-AVRT Large AP,  
inferoparaseptal-
-inferior
3 1 No
3 1 Coarctaction  
of aorta
O-AVRT Inferoparaseptal 
and CTI line  
(uncompleted 
line)
2 36 No
4 1 TVR,  
cryoablation
O-AVRT,  
A-AVRT
Large AP, right  
inferior/right  
antero-inferior
3 NA AF
AF — atrial fibrillation; AP — accessory pathway; ASD — atrial septal defect; CTI — cavotricuspid isthmus; MAP — multiple accessory pathway; 
NA — not available; O-AVRT — orthodromic atrioventricular reciprocating tachycardia; PDA — patent ductus arteriosus; RF — radiofrequency; 
TVR — tricuspid valve replacement; VSD — ventricular septal defect
The success rate of RF ablation (RFA) in pa-
tients with APs after the first procedure conducted 
in this centre was 77.3% and after the last RFA the 
rate was 95.5%. 
In the group of 7 patients who underwent 
3 or more RF procedures, there were 5 patients 
with whom the first 2 attempts which were not 
performed at this centre. 
Three patients with APs and induced s/f AVNRT 
also underwent ablation of the slow AV node pathway. 
No major early or late complications were observed.
Follow-up
Long-term follow-up was done in 19 (86.4%) 
patients with a median of 95.7 ± 49.8 (range 
10–204) months after the first ablation procedure. 
Three patients who were treated in the mid-1990s 
were lost to follow-up.
After successful ablation, the antiarrhythmic 
drugs were discontinued.
One patient died due to heart failure during 
the follow-up at the age of 72 one year after a third 
unsuccessful RFA and 13 years after unsuccessful 
Figure 5. 18-year-old patient with Ebstein’s anomaly after atrial septal defect and ventricular septal defect operation. 
Electroanatomical CARTO map of orthodromic atrioventricular reentrant tachycardia (A), bipolar voltage of the right 
atrium shows, probably post incisional, low voltage area (B).
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surgical cryoablation, which was performed dur-
ing implantation of tricuspid valve prosthesis and 
suture of an atrial septal defect. 
One patient with WPW and VF, after successful 
RFA of the APs, did not experience any arrhythmia 
episodes.
The long-term success rates were 95.5% 
of patients with APs, and 100% in patients with 
AVNRT and CTI-AFL. 
Discussion
There remains a limited number of previously 
published reports concerning long-term follow-up 
data in patients with EA and arrhythmias treated 
RFA. 
Data of patients with EA and RFCA of APs which 
were published previously reported a relatively short 
follow-up from 12 ± 7 to 54 ± 34 months [3, 4, 12, 14].
Apparently the present study has the longest 
follow-up and one of the largest cohort of patients 
with EA and APs.
The clinical outcome of this study indicates 
that in long-term follow-up after successful ab-
lation, the majority of patients were free of any 
arrhythmia episodes, ablated as well as newly 
developed.
The ablation of AP in patients with EA is chal-
lenging but when performed in an experienced 
centre the long-term follow-up is satisfactory. 
Some authors have suggested the use of 
intracardiac echo to define the true location of tri-
cuspid annulus (TA) via the right coronary artery 
(RCA) [18]. 
Others have proposed the use of guidewire 
or diagnostic catheter inserted into the RCA for 
proper delineation or mapping of TA [14]. 
These two prior techniques were not used in 
this study. Since 2002, this clinic has routinely used 
a 3-dimensional system, 8 F irrigated tip catheter 
and long sheaths and, if necessary, with 180 degree 
curvature.  
The presented outcomes (77.2% efficacy after 
the first and 95.5% after the last procedure) are 
comparable to those reported in an earlier series 
[4, 6, 12].
The percentage of patients with EA and mul-
tiple accessory pathway in this study was similar 
to those presented by other authors [3, 5, 12, 14]. 
Contrary to other studies, however, a very 
high percentage of patients with broad APs (50%) 
was found. The presence of a broad AP in a par-
ticular patient can be subjective is consequently 
difficult to quantify. 
The current guidelines itemised EA as a risk 
factor for VF in patients with AP but in a previous 
study conducted on the largest cohort of patients 
with aborted sudden cardiac death and APs thus 
far, EA was not defined as a statistically significant 
risk factor for VF [11, 19].
Limitations of the study
This is a retrospective analysis and therefore 
several limitations must be taken into account. The 
main limitations of the present study are the rela-
tively small number of patients enrolled. Secondly, 
not all detailed data concerning ablation procedures 
were available. Thirdly, precise echocardiographic 
data of patients who underwent ablation in the 
1990s were not always available. Fourthly, some 
patients were lost to follow-up.
Conclusions
The RFAs in patients with EA and APs are chal-
lenging but most arrhythmias are amenable to abla-
tion and long-term follow-up is well recommended. 
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